Finerenone in Patients with Focal Segmental Glomerulosclerosis

J Am Soc Nephrol. 2026 Nov 15. doi: 10.1681/ASN.0000001333. Online ahead of print.ABSTRACTBACKGROUND: Mineralocorticoid receptor overactivation is implicated in podocyte injury and glomerulosclerosis. In a prespecified analysis of the FIND-CKD trial, we examined the efficacy and safety of finerenone

Sodium-glucose cotransporter-2 inhibitor therapy and risk of mortality and morbidity following hospitalization for pneumonia in type 2 diabetes mellitus: An international propensity score-matched cohort study

Sage Open Chronic Dis. 2026 May 24;17:27558428261449950. doi: 10.1177/27558428261449950. eCollection 2026 Jan-Dec.ABSTRACTBACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated cardiovascular and renal benefits in type 2 diabetes mellitus (T2DM).OBJECTIVES: This study invest